PALI
HEALTHCAREPalisade Bio Inc
$2.00+0.03 (+1.52%)LIVE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving PALI Today?
No stock-specific AI insight has been generated for PALI yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.53$2.86
$2.00
Fundamentals
Market Cap$335M
P/E Ratio—
EPS$-0.30
Dividend Yield—
Dividend / Share—
ROE-0.2%
Profit Margin—
Debt / Equity—
Trading
Volume1.8M
Avg Volume (10D)—
Shares Outstanding167.4M
PALI News
20 articles- Palisade Bio Reports Additional Phase 1a/b Data Demonstrating Colon-Targeted Exposure and Sustained IC90 Coverage Supporting Once-Daily Dosing in Ulcerative ColitisYahoo Finance·May 5, 2026
- Wolfe Highlights Differentiation Potential in Palisade Bio, Inc. (PALI) Clinical ProfileYahoo Finance·Apr 17, 2026
- Palisade Bio Announces Abstract Selected for Poster Presentation at Digestive Disease Week (DDW) 2026Yahoo Finance·Apr 16, 2026
- Palisade Bio to Present at the Needham & Co. 25th Annual Healthcare ConferenceYahoo Finance·Apr 8, 2026
- TSX Penny Stocks To Watch In March 2026Yahoo Finance·Mar 31, 2026
- Update: Palisade Bio Shares Fall After Phase 1b Data on PALI-2108 in Fibrostenotic Crohn's DiseaseYahoo Finance·Mar 31, 2026
- Palisade Bio Shares Phase 1b PALI-2108 Data Showing Safety, PK and Early Crohn’s Efficacy SignalsMarketbeat·Mar 31, 2026
- Palisade Bio Reports Positive Topline Data from Phase 1b Clinical Study of PALI-2108 in Fibrostenotic Crohn’s DiseaseYahoo Finance·Mar 30, 2026
- Structure Therapeutics Slides 28% This Year as $6 Million Stake EmergesMotley Fool·Mar 22, 2026
- Palisade Bio (PALI) Reports Positive Phase 1b Data for PALI-2108 in UC PatientsYahoo Finance·Mar 18, 2026
- Palisade Bio Announces Participation in Two Upcoming Investor ConferencesYahoo Finance·Mar 2, 2026
- Palisade Bio Details PALI-2108 UC, Crohn’s Plans and Cash Runway Into 2029 at Oppenheimer ConferenceMarketbeat·Mar 1, 2026
- Palisade Bio Reports Rapid Clinical, Histologic and New Mechanistic Colon Tissue RNA Sequencing Data Supporting Targeted Activity of PALI-2108 at ECCO 2026Yahoo Finance·Feb 23, 2026
- Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory BoardYahoo Finance·Feb 17, 2026
- Palisade Bio to Participate in the Piper Sandler Virtual Novel Targets in Immunology SymposiumYahoo Finance·Feb 9, 2026
- Palisade Bio to Present at the Oppenheimer 36th Annual Healthcare Life Sciences ConferenceYahoo Finance·Feb 5, 2026
- Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory BoardYahoo Finance·Jan 29, 2026
- Palisade Bio Announces Two Abstracts Selected for Poster Presentations at Leading Global Inflammatory Bowel Disease ConferencesYahoo Finance·Jan 16, 2026
- Palisade Bio Announces Strategic Equity Investment from the Crohn’s & Colitis Foundation’s IBD Ventures Program to Advance PALI-2108Yahoo Finance·Jan 7, 2026
- Palisade Bio Announces Granting of Japanese Patent Covering Composition of Matter for Lead Product Candidate, PALI-2108Yahoo Finance·Dec 30, 2025
All 20 articles loaded
Price Data
Open$2.16
Previous Close$1.97
Day High$2.22
Day Low$1.96
52 Week High$2.86
52 Week Low$0.53
52-Week Range
$0.53$2.86
$2.00
Fundamentals
Market Cap$335M
P/E Ratio—
EPS$-0.30
Dividend Yield—
Dividend / Share—
ROE-0.2%
Profit Margin—
Debt / Equity—
Trading
Volume1.8M
Avg Volume (10D)—
Shares Outstanding167.4M
About Palisade Bio Inc
Leading BioSciences, Inc. develops therapies to improve human health through therapeutic protection of the gastrointestinal mucosal barrier. The company is headquartered in Carlsbad, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—